Vascular Biology and Tumor Microenvironment Expertise for Translational Cancer Projects

Our group offers strong expertise in tumor vasculature, endothelial cell heterogeneity and tumor microenvironment (TME) biology, with a clear translational and patient-oriented focus. We specialize in understanding how vasculature regulates tumor progression and metastatic dissemination.

We have extensive experience in advanced molecular and cellular biology, 2D/3D functional assays, in vivo cancer models, and state-of-the-art omics approaches, including single-cell and spatial transcriptomics, proteomics, and metabolomics. A key strength of our group is the integration of multi-omics data with functional validation to identify novel therapeutic targets and biomarkers.

Our team has participated in several national and European-funded research projects, collaborating closely with clinical units and hospitals to access well-annotated patient samples (FFPE, fresh tissue, blood) and to ensure rapid translation of discoveries to clinical settings. We can also facilitate connections with clinical and academic partners and contribute to proposal design, work package leadership, and translational work packages

Topic:

Interested in EU Mission Cancer / Horizon Europe calls related to:

• Tumor microenvironment

• Cancer vasculature and angiogenesis

• Immunotherapy response and resistance

• Biomarker discovery and patient stratification

• Translational and precision oncology approaches

(Open to related topics within the Mission Cancer destination)

Type of Cooperation Sought:

Partner role in a consortium (with interest in leading or co-leading scientific and translational work packages)

Additional Information:

• Strong background in European collaborative projects and multidisciplinary consortia

• Proven experience in clinical–translational research and interaction with hospitals

• Ability to contribute advanced experimental platforms and omics-based analyses

• Potential to support biomarker validation, mechanistic studies, and therapeutic target discovery

• Open to collaborating with academic, clinical, and industrial partners